ADVERTISEMENT

Indian-American gynecologist named chief scientific officer of Inception Research Institute

Daftary, who previously served as CEO at Ferring Pharmaceuticals, will lead research initiatives, including launching new pharmaceutical, device, and laboratory trials.

Gaurang Daftary. / Image - Inception Fertility.

Huston-based fertility services provider, Inception Fertility, appointed Indian-American reproductive medicine and maternal health specialist Gaurang Daftary as chief scientific officer of the Inception Research Institute. 

Daftary will lead the institute’s research initiatives, including pharmaceutical and device trials, and leverage North America’s largest EMR database to improve pregnancy outcomes. His role will involve conducting multi-center FDA randomized controlled trials and refining fertility protocols to enhance patient care.

Alice Domar, chief compassion officer of Inception, welcomed Daftary’s appointment, saying, “We are very excited to have Daftary be part of this exciting new chapter of our Institute and help uncover new therapeutics to improve pregnancy outcomes.” 

TJ Farnsworth, CEO of Inception Fertility, expressed enthusiasm for Daftary’s contributions, stating, "We are thrilled to have him as part of our research team, and we look forward to the contributions he will undoubtedly bring to this field of medicine.”

Daftary shared his excitement about his new role, adding, "I am honored to be part of the Inception Research Institute and help bring these advancements to the forefront of the industry. Over the last 20 years, we have seen the greatest advancements in reproductive medicine that are helping more and more people have babies. And yet, we recognize that there are many more opportunities to uncover even greater possibilities"


Daftary brings more than 20 years of experience in women’s reproductive health. Before joining Inception, he served as CEO of NextGenRepro, a consulting firm for reproductive medicine, and was previously global scientific vice president at Ferring Pharmaceuticals.

Daftary received his MBA from the Carlson School of Management, University of Minnesota, in 2017, and a MD from the Yale School of Medicine in reproductive endocrinology and infertility.  

The Inception Research Institute addresses key issues in reproductive medicine by focusing on advancements in patient care, pharmacological innovations, and device development. It also supports The Prelude Network, a leading clinical network for fertility services in North America, with centralized services such as IRB applications and contract reviews.
 

Comments

ADVERTISEMENT

 

 

 

ADVERTISEMENT

 

 

E Paper

 

 

 

Video